Alzheimer disease (AD) is an insidious, progressive and irreversible brain disorder. Its incidence is highest in people aged over 65, a cohort forecast to grow by 62% between 2015 and 2030 to around 1 billion worldwide. In 2015, an estimated 5.1 million people in the United States who are aged 65 or older live with AD. By 2050, this number is predicted to increase to approximately 13.8 million. Although, the cause of AD is not fully understood, current treatments for AD aim to maintain functional capability while slowing or delaying symptoms. The approved compounds for the treatment of AD include the acetylcholinesterase (AChE) inhibitors donepezil (Aricept), rivastigmine (Exelon), galantamine (Razadyne/Reminyl) and tacrine (Cognex) as well as the NMDA (N‑methyl-d‑aspartate) receptor antagonist memantine (Namenda/Axura). Currently, discounting university and public research programmes, 102 drugs are in clinical trials for the treatment of AD. These mainly consist of neuromodulatory signalling or Aβ-targeting therapies. Therapies that target neuromodulatory signalling include nicotinic acetylcholine receptor (nAChR) antagonists and AChE inhibitors, serotonergic therapies (that is, 5-hydroxytryptamine 4 (5‑HT4) agonists or 5‑HT6 antagonists), muscarinic receptor agonists and histamine receptor 3 (H3) antagonists. These are all thought to have limited clinical and commercial potential, as clinical trials have so far not shown any clear improvement in the efficacy of these drugs compared to currently approved drugs in this category. The mode of action of these drugs mainly include APP metabolism, Aβ aggregation/clearance, immune response modulator, microtubular/structural targets, neuromodulator signaling, neurotropic, and others.
The global Alzheimer’s disease treatment market segmentation is based on drug class (API) – acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine), immunoglobulin (gammagard liquid), N-methyl-daspartate (NMDA) receptor antagonist (memantine).
The global Alzheimer’s disease treatment market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global Alzheimer’s disease treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global Alzheimer’s disease treatment market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global Alzheimer’s disease treatment market and profiled in this report include Abbott Laboratories, AC Immune, Affiris, AstraZeneca, Baxter International, Biogen Inc., Bristol-Myers Squibb, Eisai, Eli Lilly, Janssen Pharmaceuticals (Johnson & Johnson), Lundbeck, Merck & Co., Neurim Pharmaceuticals, Novartis, Pfizer, Roche (Genentech), TauRx Therapeutics, vTv Therapeutics, and Warner-Lambert.